Amgen has unveiled plans to invest more than $600m in constructing a new science and innovation centre at its global headquarters in Thousand Oaks, California.
The initiative aims to strengthen collaboration among researchers, engineers, and scientists to expedite the discovery of new therapeutics for severe diseases.
The new facility will be equipped with advanced automation and digital capabilities.
It will provide scientists with the necessary tools and environment to pursue advancements in biotechnology.
Construction of the new centre is slated to begin in Q3 2025, and the project is expected to generate hundreds of US jobs.
Amgen chairman and CEO Robert Bradway said: “At Amgen, we’re continuing to invest in the future of American science and innovation.
“This new center will empower our scientists with the tools and collaborative environment they need to shape the next era of scientific discovery and advance medicines that improve human health.”
Amgen has been operating for over 45 years, based in Thousand Oaks, California, forming part of the greater Los Angeles area.
The company boasts of investing over $40bn in manufacturing and research since 2017, including more than $5bn in direct capital expenditures within the US.
The pro-growth tax policies in the Tax Cuts and Jobs Act of 2017 and the One Big Beautiful Bill Act of 2025 enhanced its ability to invest locally, said Amgen.
The announcement of the new science and innovation centre follows the US drugmaker’s recent investments in the country.
In December last year, Amgen announced $1bn investment in a second drug substance manufacturing facility in Holly Springs, North Carolina, creating 370 jobs.
In April this year, the company announced a $900m investment in the expansion of its manufacturing facility in Central Ohio, which is projected to generate 750 jobs.
